Pioneering the Future of Cell-Based Cancer Therapeutics with CAP Technology.

At Preverna, we stand at the cutting edge of oncological advancements, driven by our groundbreaking Chimeric Adaptor Protein (CAP) technology. Distinctly set apart from traditional CAR-T therapies, our CAP-T cells promise enhanced therapeutic efficacy and refined control for solid tumors.